Article info

Download PDFPDF

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

Authors

  1. a elizabeth_buchbinder{at}dfci.harvard.edu
  2. b jpd4401{at}aol.com
  3. c gdaniels{at}ucsd.edu
  4. d Brendan.Curti{at}providence.org
  5. e SPPatel{at}mdanderson.org
  6. f sgholtan{at}umn.edu
  7. g gpmile{at}cox.net
  8. h mayer.fishman{at}moffitt.org
  9. i Rene.Gonzalez{at}ucdenver.edu
  10. j JCLARK{at}lumc.edu
  11. k richartj{at}slu.edu
  12. l clao{at}med.umich.edu
  13. m stykodi{at}fhcrc.org
  14. n ann_silk{at}dfci.harvard.edu
  15. o dmcdermo{at}bidmc.harvard.edu
View Full Text

Citation

Buchbinder EI, Dutcher JP, Daniels GA, et al
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

Publication history

  • Received October 31, 2018
  • Accepted January 31, 2019
  • First published February 18, 2019.
Online issue publication 
February 18, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.